Arkin Holdings is a venture group focused on healthcare technology, investing in pharma, biotech, medical devices and digital health. It backs early-stage software-enabled healthcare companies and leverages cross-sector expertise to help portfolio firms grow. The group maintains a substantial healthcare portfolio and operates with a cross-border footprint in Israel and the United States. Its ecosystem includes Arkin Digital Health, which concentrates on software-based healthcare ventures, reflecting the group's broad exposure to health and life sciences.
Newleos Therapeutics is a stealth-mode biotechnology company focused on developing safer and more effective treatments for neuropsychiatric disorders, aiming to improve mental health outcomes.
Reunion Neuroscience
Series A in 2024
Reunion Neuroscience is a clinical-stage pharmaceutical company focused on developing therapeutic solutions for underserved mental health conditions. Its lead asset, RE104, is a proprietary psychedelic compound being developed as a potential fast-acting and durable antidepressant for patients suffering from postpartum depression and other mental health conditions.
Eleos Health
Series B in 2023
Eleos Health offers automated healthcare technology solutions. Its AI-powered Speech-to-Insights system aids clinicians in making decisions swiftly, ensuring personalized, efficient, and cost-effective patient care.
Eleos Health
Series A in 2022
Eleos Health offers automated healthcare technology solutions. Its AI-powered Speech-to-Insights system aids clinicians in making decisions swiftly, ensuring personalized, efficient, and cost-effective patient care.
Eleos Health
Seed Round in 2021
Eleos Health offers automated healthcare technology solutions. Its AI-powered Speech-to-Insights system aids clinicians in making decisions swiftly, ensuring personalized, efficient, and cost-effective patient care.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.